Voyager Therapeutics (VYGR) Getting Somewhat Favorable Press Coverage, Study Shows
Media coverage about Voyager Therapeutics (NASDAQ:VYGR) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.2630365787167 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s rankings:
- Consensus Target Price Watch for Voyager Therapeutics, Inc. (NASDAQ:VYGR) (baycityobserver.com)
- Checking the Levels on Shares of Voyager Therapeutics, Inc. (NasdaqGS:VYGR) as PI Hits 0.73287 (baycityobserver.com)
- Are Institutions Giving Voyager Therapeutics, Inc. (NASDAQ:VYGR) a Vote of Confidence? (cantoncaller.com)
- 7 Biotech Stocks Insiders Are Loading Up On (msn.com)
- James A. Geraghty Purchases 3,000 Shares of Voyager Therapeutics Inc (VYGR) Stock (americanbankingnews.com)
Several equities research analysts recently issued reports on VYGR shares. BidaskClub raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. ValuEngine raised Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Chardan Capital reissued a “hold” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, June 21st. BTIG Research reissued a “buy” rating and set a $32.00 price target on shares of Voyager Therapeutics in a research report on Thursday, June 7th. Finally, Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Voyager Therapeutics presently has an average rating of “Buy” and an average target price of $32.18.
Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.13). Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. The company had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.00 million. equities research analysts forecast that Voyager Therapeutics will post -3.13 earnings per share for the current fiscal year.
In related news, Director James A. Geraghty bought 3,000 shares of the company’s stock in a transaction on Friday, August 17th. The shares were purchased at an average cost of $18.31 per share, with a total value of $54,930.00. Following the completion of the transaction, the director now directly owns 73,588 shares of the company’s stock, valued at $1,347,396.28. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.60% of the stock is owned by company insiders.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Recommended Story: Using the New Google Finance Tool
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.